A comparison of the efficacy and safety of the combination mometasone furoate 0.1%/salicylic acid 5% ointment with each of its components in psoriasis

Journal of Dermatological Treatment

Volumn 9, Issue 3, 1998, Pages 151-156

  Katz, H I ^a   Tanner, D J ^b   Cuffie, C A ^b   Brody, N I ^c   Garcia, C J ^c   Lowe, N J ^d,e   Medansky, R S ^c   Roth, H L ^c,f   Shavin, J S ^g   Swinyer, L J ^h  

^a Minnesota Clinical Study Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UCLA School of Medicine ^*

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Skin Res Foundation of California   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Henry Ford Hospital   (United States)

^h Dermatology Research Center   (United States)

Author keywords

Mometasone furoate; Psoriasis; Salicylic acid

Indexed keywords

ANTISPOROZOAL AGENT; MOMETASONE FUROATE; SALICYLIC ACID; TETRACOSACTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; SKIN IRRITATION; SYMPTOM; TOPICAL DRUG ADMINISTRATION;

EID: 7844220621     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.3109/09546639809160546     Document Type: Article

References (9)

1. Katz HI, Prawer SE, Watson MJ et al, Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Int J Dermatol (1989) 28: 342-4.
2. Medansky RS, Brody NI, Kanot NB et al, Clinical investigations of mometasone furoate - a novel, nonfluorinated, topical corticosteroid. Semin Dermatol (1987) 6: 94-100.
3. Medansky RS, Bressinck R, Cole GW et al, Mometasone furoate ointment and cream 0.1 per cent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 per cent and triamcinolone acetonide 0.1 per cent. Cutis (1988) 42: 480-5.
4. Rosenthal D, Duke E, A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% vs betamethasone valerate ointment 0.1% in the treatment of psoriasis. Curr Ther Res (1988) 44: 790-801.
5. Svensson A, Reidhav I, Gisslén H et al, A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res (1992) 52: 390-6.
6. Greaves MW, Weinstein GD, Treatment of psoriasis. N Engl J Med (1995) 332: 581-8.
7. Weirich EG, Dermatopharmacology of salicylic acid. I. Range of dermatotherapeutic effects of salicylic acid. Dermatologica (1975) 151: 268-73.
8. Krochmal L, Wang JCT, Patel B, Rodgers J, Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol (1989) 21: 979-84.
9. Elie R, Durocher LP, Kavalec EC, Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res (1983) 11(2): 108-12.